What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.”In the company’s words, NCT06669403 on ClinicalTrials.gov
- Tested for
- Type I Diabetes, Sepsis, Community Acquired Pneumonia (CAP)
- Main trialPhase 2
- “This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.”In the company’s words, NCT06964087 on ClinicalTrials.gov
- Other names
- 15-mer peptide
Other drugs for Type I Diabetes
- TirzepatideEli Lilly · Phase 3
- Insulin icodecNovo Nordisk · Phase 3
- CadisegliatinvTv Therapeutics · Phase 3
- Stem Cell Educator therapyYong Zhao, MD, PhD · Phase 3
- VX-017Vertex Pharmaceuticals · Phase 3
- VX-880Vertex Pharmaceuticals · Phase 3
Coming up2
- Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes3
Last 90 days- 18 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT06669403
- 18 NovCompletion date moved: 2026-04 to 2027-03 · ClinicalTrials.gov NCT06669403
- 16 NovCompletion date moved: 2026-05-31 to 2027-05-31 · ClinicalTrials.gov NCT06964087
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 May 2027 | Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus | |
| Phase 1Recruiting | Mar 2027 | OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis | |
| Phase 1Completed | 27 Sep 2021 | 1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide. | |
| Phase 1Completed | 21 Feb 2024 | OPT101 in Type 1 Diabetes Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026